Clinical results (5 yrs) for Episealer® accepted for presentation at the ISAKOS 2021 Global Congress
Episurf Medical (Nasdaq: EPIS B) today announces that an abstract with results from a Swedish multicentre clinical study with 5 years’ follow-up of Episealer® Knee patients has been accepted for presentation at the upcoming ISAKOS 2021 Global Congress. The abstract, “Good Subjective Outcome And Low Risk Of Revision Surgery With A Novel Customized Metal Implant For Focal Femoral Chondral Lesions At A Minimum Of Five Years Follow-Up“, will be presented by Associate Professor Anders Stålman, Capio Artro Clinic, Stockholm, Sweden.
ISAKOS (International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine) is an international organisation with the mission to advance the worldwide exchange and dissemination of education, research and patient care in arthroscopy, knee surgery and orthopaedic sports medicine. The ISAKOS 2021 Global Congress will be held online on November 27-28.
The abstract reports on the clinical outcome of the 10 first Swedish Episealer® patients, that have undergone treatment with Episurf Medical’s individualised knee implant Episealer® for treatment of isolated chondral and osteochondral defects in the knee.
“We have now come to a stage where we see mid- to long-term results being available for presentation and publication and we are pleased that this scientific abstract with clinical results from the very first Swedish Episealer® patients has been accepted for presentation at this international congress”, says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
Tags: